Pharmacological treatment with various antiarrhythmic agents for the termination or prevention of atrial fibrillation (AF) is not yet satisfactory. This is in part because the drugs may not be sufficiently selective for the atrium, and they often cause ventricular arrhythmias. The ultrarapid-delayed rectifying potassium current (IKur) is found in the atrium but not in the ventricle, and it has been recognized as a potentially promising target for anti-AF drugs that would be without ventricular proarrhythmia. Several new agents that specifically block IKur have been developed. They block I Kur in a voltage-and time-dependent manner. Here we use mathematical models of normal and electrically remodeled human atrial action potentials to examine the effects of the blockade kinetics of I Kur on atrial action potential duration (APD). It was found that after AF remodeling, an I Kur blocker with fast onset can effectively prolong APD at any stimulus frequency, whereas a blocker with slow onset prolongs APD in a frequency-dependent manner only when the recovery is slow. The results suggest that the voltage and time dependence of I Kur blockade should be taken into account in the testing of anti-AF drugs. This modeling study suggests that a simple voltageclamp protocol with a short pulse of ϳ10 ms at 1 Hz may be useful to identify the effective anti-AF drugs among various I Kur blockers.
THE TREATMENT OF atrial fibrillation (AF) is complicated by the fact that "AF begets AF" (26) , where chronic high-frequency fibrillation causes remodeling of atrial electrophysiology with reduced action potential (AP) duration (APD) and refractory period leading to an enhanced propensity for reentry and circus movement for arrhythmogenesis. Recently, the ultrarapid-delayed rectifier current (I Kur ) has been recognized as a potential target for anti-AF drugs (17) . I Kur is carried by Kv1.5 subunits and contributes toward the repolarization of the AP in the human atrium. Since there is either little or no I Kur in human ventricular myocytes (11, 15, 24) , selective I Kur blockers may not have the adverse effects common to many potassium channel blockers that prolong APD in the ventricle and cause life-threatening ventricular arrhythmias, including Torsades de pointes (17) .
A number of I Kur blockers that demonstrate high atrial selectivity are under development and/or in clinical testing (17) . They show different effects on effective refractory period (ERP), QT interval, and rate dependence. XEN-D0101 increased atrial ERP in a positive rate-and dose-dependent manner without producing significant changes in ventricular ERP, QT intervals, or spontaneous sinus cycle length in a canine model (21) . AZD7009 induced concentration-dependent but rate-independent increases in atrial ERP in dogs, whereas ventricular ERP and QT interval increased slightly (5) . AVE0118 dose dependently caused reverse frequencydependent prolongation of atrial ERP in goat with no effect on QT interval (1) . NIP-142 prolonged atrial APD independently of stimulus frequency but shortened ventricular APD in guinea pig (16) . These different phenotypes of the effects of drugs on atrial ERP are thought to result from their diverse effects on the atrial AP.
Experimentally, I Kur blockade by drugs exhibits diverse voltage and time dependence (13, 14, 16, 19) . Previously, we have shown that various voltage-and time-dependent blockade of the rapid-delayed rectifier potassium current (I Kr ) differently affects APD prolongation in the atrium (22) . Therefore, different kinetics of I Kur blockade might be responsible for their distinct effects on the atrial AP. In this study we test this hypothesis by incorporating various kinetics of voltage-and time-dependent block of I Kur into in silico models of the human atrial AP. This study used not only a normal atrial AP model (7, 22) but also the one that incorporated the characteristics of AF remodeling (10) .
Simulation study with both models showed that voltage-and time-independent block of I Kur reproduced experimental APD prolongation behavior. The incorporation of voltage-and timedependent block of I Kur in the AF model showed that fast onset at depolarization effectively prolonged APD at any stimulus frequency, whereas slow onset and slow recovery at diastolic potentials prolonged APD in a frequency-dependent manner. These results suggest that the voltage and time dependence of the block of I Kur may be an important element in the action of effective anti-AF drugs. Therefore, we looked for a simple experimental protocol to screen I Kur blockers and found that the voltage-clamp experiment using short steps (ϳ10 ms) at a frequency of 1 Hz is useful to identify the I Kur blockers effective as anti-AF drugs.
METHODS

AP simulation.
To simulate the human atrial AP with voltage-and time-dependent block of I Kur, we used the mathematical model developed by Courtemanche et al. (7, 8) and modified by Tsujimae et al. (22) . Briefly, this model has passive properties (e.g., membrane capacitance and membrane resistance) and 12 voltage-dependent and carrier-mediated ionic currents as follows: fast sodium current (I Na), inward rectifier potassium current (IK1), transient-outward potassium current (Ito), IKur, IKr, slow-delayed rectifier potassium current (IKs), L-type calcium current (ICa,L), sarcolemmal calcium pump current (Ip,Ca), sodium-potassium pump current (INaK), sodium-calcium exchanger current (INaCa), background sodium current (Ib,Na), and background calcium current (Ib,Ca). Hodgkin-Huxley type equations are used to calculate the forward and backward kinetics of the activation and inactivation processes of each voltage-gated ion channel. The program was coded in C/Cϩϩ, and simulations were run on an IBM-compatible computer with a Cϩϩ compiler. The stimulus frequency was set to 1 Hz unless otherwise stated. Thirty APs were calculated in each simulation. The last AP in each run was used for analysis. The APD was measured at Ϫ70 mV (APD Ϫ70 mV); this closely approximates to APD at 90% repolarization.
AF-modified AP simulation. Electrical remodeling was implemented by modifying the maximum conductance of particular ion channels in the human atrial AP model (normal model) according to experimental data; thus the AF-modified AP model (AF model) showed a 70% reduction in the maximum conductance of I Ca,L (2, 3), a 50% reduction in the maximum conductance of I to, (4, 23) , a 50% reduction in the maximum conductance of IKur (4, 23) , and a 100% increase in the maximum conductance of IK1 (3, 9, 23) .
Formulation of kinetic properties of types of IKur blockade. To incorporate the effects of the voltage-and time-dependent IKur blockade, we modified the formulation of IKur given by Courtemanche et al. (7) as follows:
where yKur is the fraction of IKur that is not blocked by a drug, gKur is the maximum conductance, ua is the activation gate variable, ui is the inactivation gate variable, V is the membrane potential, and EK is the reverse potential. where onset,yKur is the time constant for yKur at large depolarized potential, recovery,yKur is the time constant for yKur at large hyperpolarized potential, and the values for the half value and slope of the Boltzmann function are Ϫ40 and 5, respectively. In this study, the voltage dependence of the steady state of I Kur blockade was fixed to isolate and examine only the effects of the time constant. Most I Kur blockers are known to exhibit voltage-dependent blockade in steady state, but their blockade at the resting potential is weak even at high drug concentrations (12, 19, 20) . In contrast, the time constant for I Kur blockade at large depolarized potential ranges from Ͻ10 ms (14) to Ͼ200 ms (20) . Similarly, the time constant for recovery from block at large hyperpolarized potential ranges from Ͻ100 ms to Ͼ4 s (14) . Therefore, to examine APD prolongation with maximum block effect, we used Eq. 3, which corresponds to a form of blockade where I Kur is not blocked at all at large hyperpolarized potential and where 90% of IKur is blocked at large depolarized potential (Fig. 1A ) and the voltage dependence of the time constant was changed by adjusting the time constant at large depolarized potential ( onset,yKur, from 5 to 160 ms) and time constant at large hyperpolarized potential (recovery,yKur, from 250 to 40 s). An example of different values of recovery and onset is shown in Fig. 1B . A simulation of a voltage-clamp pulse with a step from Ϫ80 to ϩ40 mV for 200 ms upon I Kur showed that the changes of the time constants affected the time course of IKur (Fig. 1C ) and the development of IKur blockade and the recovery from IKur blockade (Fig. 1D) .
RESULTS
We first validated our normal and remodeled human atrial myocyte AP models. The maximum conductance of I Kur was decreased stepwise from the control level so that the effect of voltage-and time-independent I Kur blockade on the AP could be analyzed (Fig. 2) . As I Kur block increased, the "dome" of the AP in the normal atrial myocyte model was augmented ( Fig.  2A, normal) , whereas the APD at Ϫ70 mV remained almost constant (Fig. 2B, normal) . On the other hand, I Kur blockade in the remodeled atrial myocyte AP model (AF model) progressively prolonged APD as the blockade was enhanced ( Fig. 2A,  AF; Fig. 2B, AF) . These characteristics are consistent with experimental (25) and previous model results (8) , and this shows that I Kur blockade has potential as an anti-AF target because of its capability to prolong APD and ERP in the remodeled atrium under chronic AF. The rest of this study concentrates on the AF model.
Voltage-and time-dependent blockade was introduced into I Kur kinetics in the AF model, and the effects of varying onset and recovery time constants of block on the remodeled AP were examined (Fig. 3) . The maximum block of I Kur was fixed at 90% (Eq. 3). Figure 3 , A and B, illustrates the effect of block-onset time constant with a fixed recovery time constant of 1,000 ms at the resting potential. The stimulus frequency was 1 Hz. The onset time constant was altered from 10 to 160 ms. APD was most enhanced at the shortest onset time constant. As the time constant was increased, the form of the AP gradually evolved toward the control (Fig. 3A) . The APD prolongation peaked at the shortest onset time constant, and the value of APD decreased to that in control as the onset time constant was increased (Fig. 3B) .
When the onset time constant was fixed at 10 ms, altering the recovery time constant from 250 ms to 40 s had little effect on APD (10 ms; Fig. 3, C and D) . Actually, even when the recovery time constant was set to the fastest value (250 ms), the APD was 170 ms (cf. 132 ms in the control). On the other hand, with an onset time constant of 160 ms, APD was only slightly prolonged (137 ms) with the recovery time constant of 250 ms. As the recovery time constant was increased, APD was gradually prolonged (160 ms; Fig. 3, C and D) , and it reached 176 ms at the recovery time constant of 40 s.
These different effects on APD prolongation were accounted for by the different kinetics of the nonblocked I Kur fraction, y Kur (Fig. 4 ). An analysis of y Kur showed that I Kur blockade during phase 0 of AP depends on the recovery time constant (Fig. 4A ). Under blockade with fast recovery kinetics of 250 ms, the recovery from block could be complete during phase 4 of AP with any onset time constant from 5 to 160 ms and the subsequent I Kur blockade during phase 0 of AP was small. But under blockade with slow recovery kinetics, the recovery from block may not be complete during phase 4 and the I Kur blockade accumulated. Actually, as the recovery time constant was increased to 1,000 or 4,000 ms, the I Kur blockade at phase 0 increased. This increase was more pronounced as the onset time kinetics was slower. However, when the onset time constant was short (ϳ5-40 ms), the maximum I Kur blockade developed during the AP did not alter significantly. In contrast, when the onset kinetics was slow (80 and 160 ms), not only the I Kur blockade at phase 0 but also the maximum I Kur blockade during the AP increased as the recovery kinetics became slower. Thus the stimulus frequency affected the consequences of the recovery from I Kur blockade when the onset time constant was slow (Fig. 4B) . A long phase 4 between APs allowed I Kur blockade to recover completely, whereas a short cycle length led to incomplete recovery. Irrespective of the recovery time constant, a fast onset of block completed the development of I Kur blockade. Therefore, it was predicted that whereas I Kur blockers with fast onset kinetics prolong APD rate independently, those with slow onset and recovery kinetics do so rate dependently.
In vitro studies of potassium channel blockers routinely use heterologous expression systems and voltage-clamp protocols to determine the effects of drugs on target ion channels. But it is difficult to directly translate results from classical voltageclamp protocols to the dynamic changes that occur in potential and currents during an AP. The final section of this study was therefore dedicated to determining whether it was possible to design a voltage-clamp protocol that would reflect the effect of I Kur blockers on APD and which could then be used to identify I Kur blockers with fast onset and/or slow recovery kinetics. Figure 5A , left, shows the results of simulating I Kur within the AF-atrial myocyte model with a voltage-clamp step protocol (200 ms in duration). Running the simulation of I Kur block with different onset time constants clearly shows that at anything but the slowest onset rates (80 and 160 ms), I Kur block achieved saturation before the end of the 200-ms voltage step. Therefore, it was not possible to relate the relative amount of current recorded at the end of the voltage step (13, 16, 19) to the effect of equivalent block on APD ( Fig. 5B; open squares) . On the other hand, repeating these simulations with a 10-msduration voltage step (Fig. 5A, right) gave information that provided a more predictive relationship between the amount of current remaining at the end of the voltage step and the effect of this time course of the onset of block on APD ( Fig. 5B;  asterisks) . These results indicate that the length of a step must be carefully set if voltage-and time-dependent blockade is involved in drug action.
The next step was to identify protocols that could decorticate the effects of the kinetics of recovery from block. Figure 5C illustrates the effects of simulating voltage-clamp step stimulation of I Kur at different stimulus frequencies and with different time constants for recovery from block. The duration (200 ms) and holding voltage (0 mV) were selected to correspond to those of plateau in human atrial AP after electrical remodeling. The onset time constants of I Kur block were those shown in Fig.  5A . It is clear that increasing stimulus frequency and/or recovery time constant lead to the accumulation of I Kur block with successive stimuli. We then changed the duration of the last step to 10 ms and calculated its step end current. Figure 5D exhibits the relationship between relative-step end currents and APD for two block-onset time constants (10 ms, open triangles; and 160 ms, open circles) while varying recovery time constant. In both cases the reduction in voltage-clamp current associated with longer recovery from block reflected an increase in APD in the AP simulation. In conclusion, a shortduration voltage-clamp step is able to identify the various kinetic parameters of block of I Kur that might be useful to screen pharmaceutically interesting compounds.
DISCUSSION
This study used an AF-remodeled human atrial AP mathematical model to examine the effects of voltage-and timedependent kinetics of I Kur block on atrial AP configuration to identify the characteristics required for effective anti-AF drugs. In this simulation, I Kur blockers with fast onset would prolong APD rate independently and those with slow onset are expected to prolong APD rate dependently, when the recovery is slow recovery. To aid fast and effective screening for compounds with these characteristics, a voltage-clamp protocol with a 10-ms step is more useful than the conventional 200 -500-ms step.
Advantages of model studies. In silico studies are not intended to replace either in vitro or clinical trials during drug development, but they can reduce the number of animal and human experiments and orientate screening methods toward identifying compounds with maximally effective characteristics. For example, it is generally accepted that the quantity and the quality of human atrial tissue available for in vitro studies are extremely limited, and this situation is even worse when samples of AF-remodeled material are required. Advances in the therapeutic treatment of AF are also hindered by the absence of a clinically relevant animal model of this pathology (6) . Although the shortening of APD in sinus rhythm due to an indirect enhancement of I Ca during the profoundly elevated plateau was not reproduced in this study (25) , the normal and AF atrial myocyte models used in this study reproduced experimental effects of I Kur block on the human atrial AP (Fig. 2) , and further in silico studies of drug effects on these simulations of the human atrial AP may reduce the need for a number of in vitro experiments. Furthermore, with in silico studies, it is possible to examine hypothetical effects of drugs, both good and bad. Thus I Kur blockers with slow onset and fast recovery can be excluded from further consideration.
Optimal anti-AF drug profile predicted from the model study: fast onset and slow recovery. This study suggests that conventional voltage-clamp experiments with a long step (ϳ200 ms) may fail to capture the properties of I Kur blockers, which indicate their potential as effective anti-AF drugs. In previous in vitro experiments, long voltage-clamp steps were used to emphasize the I Kur blocking potency of different compounds (13, 14, 16, 19) . However, the results of this study suggest that for I Kur blockers to effectively treat chronic AF, they should exhibit fast onset kinetics during systole or both slow onset during systole and slow recovery during diastole. Although this point has not been considered in previous studies, I Kur blockers under trial for AF (e.g., AVE0118) do show fast development of block and thus fit at least part of this profile (13) . Short voltage-clamp steps of 10-ms duration detect this particular property of anti-AF I Kur blockers.
The recovery time constant of I Kur blockade is not usually considered as a factor in the development of an anti-AF drug. However, it clearly plays a role in the frequency dependence of APD prolongation by a drug. Most strategies for the development of selective I Kur blockers as anti-AF drugs do not aim to be effective within a specific AP frequency band; rather, the same drug is expected to terminate AF and to prevent the reoccurrence of AF after the return to sinus rhythm. The fast onset time constant may fit into this strategy. On the other hand, a frequency-dependent elongation of APD due to slow recovery from block may be a desirable characteristic for a compound to prevent fibrillation. Because of the major overlap of I Kur and I to for the repolarization reserve in atrial AP, the frequency dependence of APD elongation in native human AF atrium caused by I Kur blockers with different blocking and recovery kinetics would be more complicated than that proposed in this study. Although I to is known to be less sensitive to I Kur blockers (e.g., Ref. 18) , it is possible to examine the effects on APD and its frequency dependence of possible overlapped I to and I Kur blockades with our human atrial AF model by further introducing I to blockade into the model. However, for the final conclusion, it is needed to confirm the feasibility of this concept in native AF human atrial myocytes or tissue.
Different effects of I Kur blockade on atrial AP in human and animals. Different potassium channels contribute differently to cardiac AP repolarization in different species, in different parts of the heart, and during or following different pathologies. The combination of the potassium currents (e.g., I Kr , I Ks ) and calcium currents contributing to AP repolarization is known as its repolarization reserve. Thus blockade of I Kur did not induce significant APD prolongation in the model of the normal human atrial AP because strong activation of I K during normal APD conceals the effect of I Kur blockade. AF remodeling reduced I Ca,L and shortened APD, and weak activation of I K due to shortened APD could not compensate for blockade of I Kur , which then prolonged APD. In a similar manner the effects of I Kur block on APD in animals will depend on the particular combination of potassium currents and the physiological conditions regulating the repolarization reserve. In animals with short APDs, APD prolongation due to I Kur blockade could be overestimated and drug efficacy may not reflect the situation in human. Models of the human heart can assist to resolve such problems in drug development.
